Argus Research Maintains Integra Lifesciences Holdings Corp to Buy with Price Target $105.00

Brokerage firm Argus Research Maintains its rating on Integra Lifesciences Holdings Corp(NASDAQ:IART). In a research note issued to the investors, the brokerage major Raises the price-target to $105.00 per share. The shares have been rated Buy. The rating by Argus Research was issued on Sep 23, 2016.

In a different note, On Jul 29, 2016, Barclays said it Maintains its rating on Integra Lifesciences Holdings Corp. In the research note, the firm Raises the price-target to $77.00 per share. The shares have been rated ‘Equal-weight’ by the firm. On Jul 29, 2016, Jefferies said it Maintains its rating on Integra Lifesciences Holdings Corp. In the research note, the firm Raises the price-target to $81.00 per share. The shares have been rated ‘Buy’ by the firm. JP Morgan said it Initiates Coverage on Integra Lifesciences Holdings Corp, according to a research note issued on Jul 13, 2016. The shares have been rated ‘Overweight’ by the firm.

Integra Lifesciences Holdings Corp (IART) made into the market gainers list on Tuesdays trading session with the shares advancing 0.41% or 0.35 points. Due to strong positive momentum, the stock ended at $86.02, which is also near the day’s high of $86.135. The stock began the session at $85.87 and the volume stood at 4,74,741 shares. The 52-week high of the shares is $88.86 and the 52 week low is $54.75. The company has a current market capitalization of $3,214 M and it has 3,73,60,514 shares in outstanding.

Integra Lifesciences Holdings Corp(IART) last announced its earnings results on Jul 28, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $249.31M. Analysts had an estimated revenue of $243.17M. Earnings per share were $0.79. Analysts had estimated an EPS of $0.76.

Several Insider Transactions has been reported to the SEC. On Aug 25, 2016, Raymond G. Murphy (director) sold 2,600 shares at $86.64 per share price.Also, On Aug 10, 2016, Peter J Arduini (President & CEO) sold 24,009 shares at $84.54 per share price.On Aug 9, 2016, Daniel L. Reuvers (Corp VP, Pres. International) sold 418 shares at $85.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company offers solutions such as orthopedic extremity surgery neurosurgery spine surgery and reconstructive and general surgery. The Company’s operating segments are: Specialty Surgical Solutions and Orthopedics and Tissue Technologies. The Company’s Specialty Surgical Solutions segment includes the Neurosurgery business and the Instruments business. The Company’s Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair bone and joint fixation implants in the upper and lower extremities bone grafts and nerve and tendon repair. The Company sources its handheld surgical instruments and specialty metal and pyrocarbon implants through third-party vendors. The Company manufactures its products in plants which are located in the United States Puerto Rico France Germany Ireland and Mexico.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Integra Lifesciences Holdings Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Integra Lifesciences Holdings Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.